Project description
Medical innovation to prevent blood loss by enhancing coagulation
Massive loss of blood can occur upon trauma, surgery, childbirth, disseminated intravascular coagulation, gastrointestinal bleeding, etc. Recent studies have shown that urgent transfusion of regular plasma fails to stop massive bleeding, while other treatments are less efficient and result in increased mortality risk. The EU-funded ClearPlasma project is developing an innovative filtration system which modifies human plasma and improves the treatment of massive bleeding and bleeding disorders. The filtration extracts plasminogen, a critical protein component responsible for dissolving blood clots, enhancing coagulation and improving haemostasis, which significantly reduces bleeding. ClearPlasma is a disposable filter that can be incorporated in current clinical practices using apheresis systems. Current phase 1 of the project advances the broad development plan.
Objective
Each year, almost 2 million people die from haemorrhaging, or blood loss. Massive blood loss can occur upon: Trauma, Surgery, Childbirth, Disseminated Intravascular Coagulation (DIC), Gastrointestinal Bleeding, etc. In all of these cases, there is an urgent need for efficient plasma transfusion to halt the bleeding. However, recent studies have shown that regular plasma fails to stop massive bleeding, while other treatments show low efficacy and increased mortality risk.
ClearPlasma is an innovative filtration system that modifies human plasma to improve the treatment of massive bleeding and bleeding disorders. By extracting plasminogen, an important protein responsible for dissolving blood clots, ClearPlasma enhances coagulation and favours haemostasis, thus reducing bleeding of 55%. This translates into the opportunity to reduce up to 45% the units of plasma needed during transfusion, hence reducing treatment costs. ClearPlasma is a disposable filter that can be incorporated in current Apheresis systems thus not affecting common clinical practices. ClearPlasma addresses the Global Blood Transfusion Diagnostics Market, which was valued at approximately € 3.2bn in 2017, and is expected to reach around € 4.7bn by 2024, growing at a CAGR of 6.2% between 2018 and 2024.
The proposed work in Phase 1 of the SME instrument fits into our overall plan to reach the market by contributing the financial resources needed to plan a fast sound wider deployment of ClearPlasma and its market uptake.
Fields of science
Programme(s)
Funding Scheme
SME-1 - SME instrument phase 1Coordinator
1600101 Nazareth
Israel
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.